Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences Corp. (NASDAQ: EXAS) presented new data supporting its Precision Oncology portfolio at the 2022 San Antonio Breast Cancer Symposium (SABCS). Key highlights include results from the TAILORx and RxPONDER trials, demonstrating the Oncotype DX Breast Recurrence Score test's ability to identify patients who may not benefit from chemotherapy. A new investigational test for predicting radiotherapy benefits was also discussed. The findings reaffirm the use of genomic tests in guiding treatment decisions, potentially enhancing patient outcomes.

Exact Sciences Corp. (Nasdaq: EXAS) reported record revenue of $523 million for Q3 2022, marking a 15% increase from 2021. Excluding COVID-19 testing, revenue rose 20%, with Screening revenue at $361 million and Precision Oncology at $151 million. The company raised its full-year revenue guidance by $33 million and lowered operating expense guidance by $113 million. Expecting to reach adjusted EBITDA profitability by Q3 2023, Exact Sciences highlighted the strong performance and innovative potential of its cancer diagnostic tests.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several investor conferences in November 2022. Key events include a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on November 8 at 2:35 p.m. ET, the Jefferies London Healthcare Conference on November 15 at 10:50 a.m. ET, and the Evercore ISI HealthCONx Conference on November 29 at 1:50 p.m. ET. Additionally, a session at the Piper Sandler 34th Annual Healthcare Conference will occur on November 30 at 4:30 p.m. ET. Investors can access the webcasts via the company's website.

Exact Sciences Corp. (NASDAQ: EXAS) presented new data at the ACG Annual Meeting showcasing the impact of eliminating patient costs for follow-up colonoscopies. The findings suggest that a cost-free approach could significantly increase colorectal cancer screening rates, with over 900 deaths averted per 1 million people screened. Additionally, Cologuard was highlighted for its effectiveness in detecting serrated polyps, and its role in redefining false positive outcomes in stool tests was discussed. The new evidence reinforces Cologuard as a valuable non-invasive screening option in the fight against colorectal cancer.

Exact Sciences Corp. (Nasdaq: EXAS) announced the release of its third quarter 2022 financial results, scheduled for November 3, 2022, after U.S. market close. Management will discuss the results and business updates during a webcast at 5 p.m. ET the same day. Investors can access the live webcast through the company's website. Exact Sciences focuses on cancer screening and diagnostics, leveraging products like Cologuard^® and Oncotype^®. Further information can be found on their official site.

Exact Sciences (Nasdaq: EXAS) showcased a multi-cancer early detection study at the ESMO Congress, reporting a sensitivity of 61% and a specificity of 98.2%. This study validates a multi-biomarker approach to identify cancer across 15 organ sites, improving early detection, particularly in stages I (31.4%) and II (45.8%). With no recommended screening for 70% of cancers and as cancer remains a leading cause of death, these findings support the future of cancer diagnostics. Exact Sciences will initiate the largest registrational trial, SOAR, in 2023 to further explore these results.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in the Baird Global Healthcare Conference set for September 13, 2022, at 3:45 p.m. ET. Investors can join the fireside chat via webcast on Exact Sciences' investor relations website. The company focuses on innovative cancer screening and diagnostic solutions, enhancing its product pipeline, including Cologuard® and Oncotype® tests, to support patients through their cancer journeys. For more details, visit www.exactsciences.com.

Exact Sciences reported second quarter revenue of $521.6 million, up 20% from $434.8 million in 2021. Excluding COVID-19 testing, revenue rose 26%, driven by a 34% increase in Screening revenue to $353.9 million, and a 12% increase in Precision Oncology revenue to $154 million. Despite this growth, the company recorded a net loss of $166.1 million, or $0.94 per share. The updated 2022 revenue outlook is between $1,980-$2,022 million, reflecting adjustments in Precision Oncology projections.

Exact Sciences Corp. (NASDAQ: EXAS) announced a collaboration with the West German Study Group (WSG) to conduct a multicenter validation study on minimal residual disease (MRD) in hormone receptor-positive, HER2-negative early breast cancer patients. The ADAPT Triad study aims to utilize Exact Sciences' ctDNA liquid biopsy test for detecting MRD, involving data from about 3,000 patients. This initiative supports Exact Sciences' goal to develop clinically validated MRD tests, enhancing treatment decisions and patient outcomes.